We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Justice Department filed a motion to intervene in a multistate antitrust lawsuit accusing six generics makers of colluding to raise the prices of the antibiotic doxycycline hyclate and the diabetes drug glyburide. Read More
A federal appeals court temporarily suspended a permanent injunction that bars Sanofi and Regeneron from selling their cholesterol drug Praluent, pending a final ruling on an appeal. Read More
Eli Lilly & Co. had their patent sustained by a federal appeals court, barring generics manufacturer Teva Pharmaceuticals from marketing its own version of the billion-dollar cancer drug Alimta. Read More
A federal judge validated Shire’s patent on its delayed-release Lialda, ruling that Mylan infringed two of the patent’s claims when seeking to launch a generic of the bowel disease drug. Read More
Merck has agreed to pay Bristol Myers Squibb and Ono Pharmaceutical $625 million, plus royalties on global Keytruda sales, to resolve patent-infringement allegations involving an antibody designed to treat cancer by reactivating the body’s anti-tumor immune response. Read More
Teva’s subsidiary Barr Laboratories agreed to pay $225 million to settle a class action lawsuit alleging it reached pay-for-delay settlements that postponed the launch of generic versions of Bayer’s antibiotic Cipro. Read More
The Supreme Court has agreed to hear a case centered on whether a 180-day notification is mandatory or optional — when the appropriate disclosures are made — before a biosimilar launch. Read More
In a setback for generics makers, AstraZeneca prevailed in a patent-infringement lawsuit when a federal judge validated the company’s patent for the diabetes drug Onglyza. Read More